Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Oncologists Stories

2013-10-03 23:02:23

Ashutosh K. Tewari, MD, Named Director of Urology at Icahn School of Medicine at Mount Sinai New York, NY (PRWEB) October 03, 2013 Ashutosh K. Tewari, MB BS, one of the foremost leaders in robotic prostate surgery and prostate cancer research in the world, will serve as Chairman of The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, effective October 15, 2013. “Dr. Tewari is a top-flight urologist and physician scientist of national and...

2013-09-26 23:25:48

Larry Kun, M.D., to oversee all aspects of patient care and clinical services at the hospital MEMPHIS, Tenn. (PRWEB) September 26, 2013 St. Jude Children’s Research Hospital officials have named Larry Kun, M.D., an internationally recognized radiation oncologist, as clinical director and executive vice president. Kun will guide all aspects of clinical care and oversee clinical operations, clinical effectiveness practices and patient care quality programs for the 7,800 patients who are...

2013-09-26 12:29:22

Larry Kun, M.D., to oversee all aspects of patient care and clinical services at the hospital MEMPHIS, Tenn., Sept. 26, 2013 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital officials have named Larry Kun, M.D., an internationally recognized radiation oncologist, as clinical director and executive vice president. Kun will guide all aspects of clinical care and oversee clinical operations, clinical effectiveness practices and patient care quality programs for the...

2013-09-18 12:30:51

AUSTIN, Texas, Sept. 18, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today its collaboration with US Oncology Research to conduct a pivotal Phase III Trial for colorectal cancer. Through the collaboration, US Oncology Research will leverage its national network of affiliated oncology centers to treat patients with XBiotech's new anti-cancer therapy and report clinical outcomes. Patients enrolled in the trial will receive at least the current...

2013-09-18 08:29:52

Awards to be presented at Cancer Research Institute's 60th anniversary gala NEW YORK, Sept. 18, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit committed to developing immune system-based cancer treatments, is presenting two of its highest honors for advancing cancer immunology to Dr. Michael Karin, professor of pharmacology at University of California, San Diego, and Dr. Jill O'Donnell-Tormey, CEO and director of scientific affairs at CRI. They...

2013-09-10 04:22:15

- Company to Proceed with 2013 Commercial Launch of Novel Prostate Cancer Prognostic Test - CAMBRIDGE, Mass., Sept. 10, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a privately-held biotechnology company, today announced positive results from a large clinical validation study of ProMark(TM), its biopsy-based prostate cancer prognostic test. The study, conducted in collaboration with Fred Saad, M.D., F.R.C.S., Professor and Chief, Division of Urology, Director of Urologic Oncology,...

2013-09-06 20:20:58

Abraxane now part of standard-of-care for patients with advanced pancreatic cancer, following studies at the Virginia G. Piper Cancer Center at Scottsdale Healthcare SCOTTSDALE, Ariz., Sept. 6, 2013 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). (Logo:...

2013-09-02 00:20:34

SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(®) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with...

2013-08-21 12:28:15

Outstanding Contributions to Cancer Immunotherapy to be Recognized at CRI's 27th Annual Awards Dinner NEW YORK, Aug. 21, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit committed to developing immune system-based cancer treatments, is presenting serial tech entrepreneur and philanthropist Sean Parker and MedImmune biotech head Dr. Bahija Jallal with its highest honor for people exceptionally dedicated to advancing cancer research. They will...

2013-08-12 09:51:39

The multipronged approach directly attacks cancer cells, blocking the growth of cancer-supporting blood vessels and stimulating an antitumor immune response A unique nanoscale drug that can carry a variety of weapons and sneak into cancer cells to break them down from the inside has a new component: a protein that stimulates the immune system to attack HER2-positive breast cancer cells. The research team developing the drug – led by scientists at the Nanomedicine Research Center, part...